Diabetic retinopathy is the leading cause of blindness in the under 65s,
Introduction
Diabetes is soon to reach epidemic proportions worldwide, with an anticipated burden of over 200 million cases by 2010. 1 The chronic complications of diabetes account for much of the morbidity and mortality associated with the disease, with retinopathy being one of the most common, and most feared. 2, 3 Pathogenesis and treatment of diabetic retinopathy The pathogenesis and exact mechanisms for the development of diabetic retinopathy are complex and not fully understood. Ischaemia, changes in vascular permeability and elaboration of growth factors resulting in angiogenesis appear to be key features. 4 There are several mechanisms by which hyperglycaemia can lead to the pathological processes of diabetic retinopathy, including synthesis of diacylglycerol, itself resulting in protein kinase C activation, increased advanced glycation end product expression, oxidative stress and increased activation of the aldose reductase pathway. All these pathways upregulate cytokine expression, which is probably largely responsible for the angiogenic abnormalities of retinopathy. 5 It is unsurprising, therefore, that efforts to reduce both the incidence and progression of retinopathy have largely focussed on testing and implementing improvements in glycaemic control. 6, 7 However, with the increasing recognition of the strong vascular component to the genesis of complications, and the finding that antihypertensive therapy has, if anything, a greater and more immediate impact on both nephropathy and retinopathy, attention has become focussed on exploring haemodynamic interventions in diabetes. Of particular interest are blockers of the renin-angiotensinaldosterone system (RAAS), as several studies have shown the remarkable impact of such agents, in particular angiotensin-converting enzyme (ACE) inhibitors, in reducing the incidence and progression of the microvascular complications. It is suggested that the impressive beneficial effect of these agents is not simply due to blood pressure (BP) lowering alone, but that other haemodynamic mechanisms, specific to the RAAS, are involved. 8 This earlier work has largely focussed on diabetic nephropathy, but the EURODIAB Controlled trial of Lisinopril in Insulin-dependent Diabetes (EUCLID) study in Type 1 diabetes, and United Kingdom Prospective Diabetes Study (UKPDS) in Type 2 diabetes, both indicate that this may be true for retinopathy. 9, 10 These impressive findings require confirmation by a definitive clinical trial, and the Diabetic Retinopathy Candesartan Trials (DIRECT) Programme, the protocol for which is presented in this issue, is designed to do this.
The systemic and local reninangiotensin system
The systemic RAAS is known to play an important role in BP and electrolyte homeostasis. In recent years, local renin-angiotensin systems (RAS) have been identified in several organs including the heart, adrenal gland, ovary and thymus. [11] [12] [13] [14] There is also compelling evidence of an intracrine RAS in the eye.Ward et al. described the presence of biologically-active ACE, isolated from pig retinal vessels, as early as 1979, 15 and since then, renin, angiotensinogen and ACE have been identified in the eyes of humans, rats and rabbits. 16, 17 In human eyes, the mRNA for renin, ACE and angiotensinogen have all been isolated, suggesting that, in humans, there is local production of these constituents. 16 Further, angiotensin II (Ang II) receptors have been identified in the retinae of several animal models, 18, 19 and local levels of Ang II in the eye are several-fold higher than that in the serum, 17, 20 supporting the belief that it has important local effects which are not directed by circulating levels. The role of the local RAS in the eye appears to be in the regulation of blood flow 21 and intraocular pressure, since renin inhibitors and ACE inhibitors lower this pressure. 22, 23 Ang II is also a powerful growth factor for vascular smooth muscle cells 24, 25 and causes angiogenesis in a number of tissues, 26 although the exact mechanism remains unclear.This does, however, support the notion that the effect of the RAAS on the vasculature, and in particular the microvascular complications of diabetes, may be mediated by factors other than BP alone.
Several studies now suggest that circulating measures of the RAAS, in particular renin and prorenin, are associated with the severity of diabetic microvascular complications, and may indeed precede their onset. [27] [28] [29] [30] However, elements of the eye RAS also appear to be consistently elevated in diabetes. In rat models of diabetes, levels of ACE within the retinal vessel were significantly increased compared with the non-diabetic controls. 31 In diabetic humans, local levels of prorenin and Ang II appear to be elevated when compared with non-diabetic individuals, and these levels closely correlate with the severity of diabetic retinopathy.
32,33
Vascular endothelial growth factor Vascular endothelial growth factor (VEGF) is an endothelial cell selective angiogenic and vasopermeability factor that has been centrally implicated in the pathogenesis of diabetic retinopathy. [34] [35] [36] Levels of VEGF correlate well with degree of retinopathy, and have been shown to fall after photocoagulation therapy. 35 VEGF secretion is stimulated by hypoxia 37 and its effects are mediated via two distinct receptors, the VEGF Receptor 1 (fmslike tyrosine kinase; flt) and VEGF receptor 2 (fetal liver kinase-1; flk-1). 38 The flk-1 receptor plays a major role in angiogenesis, endothelial mitogenesis and regulation of vasopermeability, which does not appear to be shared with flt. 39, 40 Antagonising the effect of VEGF with a soluble VEGF-chimera suppresses neo-vascularisation in animal models of retinopathy of prematurity, 41 establishing a causal relationship, although this has not yet been confirmed in animal models of diabetic proliferative retinopathy. Several aetiological factors, implicated in the progression of diabetic retinopathy, have been shown to increase VEGF expression. These include glucose, 42 advanced glycation end products 43 transforming growth factor-beta 1 (TGF-β1) 44 and Insulin-like Growth Factor 1 (IGF-1), 45 all independently of hypoxia. In addition, IGF-1 appears to play a permissive role at the level of mitogen activating protein kinase (MAPK) activation, a potent stimulator of cellular proliferation, via protein kinase C.
Interaction between the retinal RAS and VEGF
A direct relationship between the RAS and VEGF is becoming clearer. Vascular smooth muscle upregulates expression of VEGF after stimulation with Ang II 46 via induction of retinal VEGF mRNA, with an associated increase in retinal vascular permeability to albumin. This requires conditions of hyperglycaemia 47 or oxidative stress, 48 both of which are present in diabetes, and is mediated through the Ang II Type 1 (AT 1 ) receptor 46 ( Figure  1 ). The increased concentration of VEGF in response to Ang II stimulation has also been demonstrated in other organs, such as cardiac endothelial cells 49 and the renal mesangium. 50 In diabetic rats, retinal vascular wall ACE increases simultaneously and incrementally with VEGF and Flk-1. 31 Ang II stimulation of bovine retinal microcapillary endothelial cells, interestingly, did not result in a rise in VEGF expression itself or VEGF mRNA; however, there was still a rise in VEGFinduced cell growth and tube formation, which was mediated through an increase in the Flk-1 receptor expression, with no alteration in its binding capacity or half-life. 19 ACE inhibition is associated with lower vitreous VEGF concentrations in both experimental diabetes 51 and patients with proliferative diabetic retinopathy. 52 This appears to be independent of the circulating plasma VEGF, which does not appear to be significantly altered by ACE inhibition. 53 Whether the effects of ACE inhibition on retinal angiogenesis are solely mediated via changes in VEGF remains unclear. In rat models of retinopathy of prematurity, ACE inhibition prevented new vessel growth by reducing VEGF expression and Flk-1 expression. 54 Although AT 1 -receptor blockade also prevented neovascularisation in retinopathy of prematurity, it appeared to do so without affecting levels of VEGF or Flk-1. but that effects may be mediated via the AT 2 -receptor, which has known anti-proliferative effects. 55 Secondly, that neovascularisation may, in part, be a consequence of vasopermeability modulated via AT 1 -receptor stimulation.The results of this study, however, were in contrast to those seen with the Ang II receptor blocker, candesartan, in strokeprone spontaneously hypertensive rats with streptozocin-induced diabetes. In this model, the retinal concentration of VEGF mRNA, significantly higher in untreated animals than non-diabetic animals, was reduced by treatment with candesartan cilexetil and was associated with a reduction in latencies of oscillatory potential peaks, a marker of functional impairment in diabetic retinopathy. 56 These findings were independent of BP and hyperglycaemia.
Other effects of the RAAS
Other effects of Ang II, separate to those associated with VEGF, include stimulation of angiopoietin-2 expression in retinal vascular cells, again mediated through the AT 1 -receptor. 57 Signalling events activated through this receptor include production of diacylglycerol, which in turn activates protein kinase C (PKC). 42 Ang II also activates mitogen-activated protein kinase (MAPK). Inhibitors of MAPK and PKC block Ang II-induced angiopoietin-2 expression. 57, 51 Finally, Ang II increases the expression of IL-6 and TGF-β1 mRNA in rat models via the AT 1 -receptor, at least in the kidney. 58 Both of these have been implicated as stimulants of VEGF in retinopathy. 44 
Conclusions
Blockers of the RAAS appear to be particularly effective in reducing the risk of the microvascular complications of diabetes, and while much of the interest to date has centred on nephropathy, it is clear that retinopathy may also benefit from such intervention. The impressive effect of such agents may be due to more than lowering of systemic BP. There is now little doubt that there are locally functioning RASs within the eye and other organs. In the eye, this appears to interact with VEGF, causing hyperpermeability and angiogenesis, the cardinal features of diabetic retinopathy. Future studies should be aimed at exploring the interaction between the eye RAAS and VEGF expression, in order to further our understanding of the aetiology of retinopathy, and providing additional therapeutic clues.
